Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

COGNItive Function in patients with gynecological Tumors

Investigators

PI: Prof. Dr. Karen Steindorf

Co-PI: Prof. Dr. Andreas Schneeweiss, Dr. Dr. Philipp Zimmer

Biometrics: Dr. Martina Schmidt

Abstract

Up to 80% of all cancer patients complain about cognitive impairments during medical treatment, known under the term "chemobrain". About 35% of all patients still describe cognitive deficits even years after the end of treatment, mainly manifesting in memory and concentration deficits, which do not only make returning to work difficult but ultimately reduce the quality of life of those affected.

Despite the great relevance of the topic, little is known about the exact causes and mechanisms so far. Although studies have shown structural changes of the brain after various types of medical treatment, there is a large discrepancy between subjectively and objectively measured cognitive impairments. It is also unclear whether cognitive impairments are exclusively caused by medical treatment or whether they are also influenced by psycho-social factors (anxiety, depression, fatigue, sleep disorders, physical activity). Due to the use of both heterogeneous objective and subjective cognitive measures as well as an inadequate recording of influencing factors and biological mediators the informative value of the studies conducted so far is limited.

Against this background, the CogniFiT study will include objective measurements of cognitive functions as recommended by the International Cancer and Cognition Task Force (ICCTF) in combination with an established questionnaire on subjectively perceived cognitive performance. Furthermore, potential biological and psycho-social influencing factors before and after cancer therapy in patients with different gynecological tumor types will be investigated.

Over a period of 36 months, 200 patients at the NCT will undergo these assessments. The results of the study will not only provide information on the severity of cognitive impairments but also on their causes and mechanisms. They will form the basis for effective preventive and supportive therapy measures and may also mitigate patients' fear of cognitive deficits.

Current status

Recruitment ended at the beginning of March 2022. The data are currently being evaluated.

Contact

Bettin Rhein
phone: +49 6221 56 32962
e-mail: cognifit@nct-heidelberg.de

Dr. Martina Schmidt
phone: +49 6221 42 2220
e-mail: m.schmidt@dkfz.de

to top
powered by webEdition CMS